Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E13.16 EPS (ttm)3.81 Insider Own0.10% Shs Outstand1.64B Perf Week0.93%
Market Cap82.20B Forward P/E8.02 EPS next Y6.25 Insider Trans0.79% Shs Float1.63B Perf Month5.12%
Income6.23B PEG2.68 EPS next Q1.06 Inst Own83.20% Short Float8.22% Perf Quarter2.41%
Sales23.86B P/S3.45 EPS this Y28.70% Inst Trans3.57% Short Ratio10.59 Perf Half Y2.35%
Book/sh9.81 P/B5.10 EPS next Y45.97% ROA15.60% Target Price57.88 Perf Year-18.56%
Cash/sh17.88 P/C2.80 EPS next 5Y4.90% ROE42.10% 52W Range42.48 - 63.69 Perf YTD-3.67%
Dividend1.64 P/FCF22.67 EPS past 5Y14.50% ROI25.40% 52W High-21.38% Beta0.70
Dividend %3.28% Quick Ratio3.70 Sales past 5Y6.60% Gross Margin71.10% 52W Low17.87% ATR0.93
Employees23300 Current Ratio3.90 Sales Q/Q10.00% Oper. Margin30.70% RSI (14)71.84 Volatility1.53% 1.95%
OptionableYes Debt/Eq1.56 EPS Q/Q286.80% Profit Margin26.00% Rel Volume0.63 Prev Close49.86
ShortableYes LT Debt/Eq1.52 EarningsJul 25 BMO Payout42.70% Avg Volume12.68M Price50.07
Recom2.20 SMA203.22% SMA507.50% SMA2004.17% Volume8,009,972 Change0.42%
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Sep-19-19 01:29PM  Does Bristol-Myers Squibb Company's (NYSE:BMY) CEO Pay Reflect Performance? Simply Wall St.
11:15AM  11 Most Aggressively Shorted Stocks Benzinga
11:05AM  Stock Investors: Do You Need a Late Cycle Plan? Zacks
08:09AM  Bristol-Myers Squibb Is Set to Emerge From a Basing Pattern
06:59AM  Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers Business Wire
Sep-18-19 10:04AM  Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis Zacks
Sep-17-19 05:45PM  Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
11:05AM  Novartis Announces New Data on Spondylitis Drug Cosentyx Zacks
Sep-16-19 10:43AM  AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure Zacks
Sep-13-19 10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
09:36AM  Renal Cell Carcinoma Space in Focus: Some Key Developments Zacks
04:47AM  Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) Zacks
Sep-12-19 07:25PM  Seth Klarman's Favorite Health Care Stocks
05:46PM  Gilead Tops List of Most Innovative Drug Companies
01:36PM  2 Large-Cap Companies Declare Dividends
10:02AM  Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus Zacks
09:20AM  Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb Zacks
09:09AM  Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug Zacks
07:59AM  Top Ranked Income Stocks to Buy for September 12th Zacks
07:43AM  Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks Zacks
06:59AM  Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019 Business Wire
Sep-11-19 05:45PM  Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
05:39PM  Bristol-Myers Squibb Board Announces Election of Three New Directors Business Wire
04:16PM  BristolMyers Squibb Announces Dividend Business Wire
12:05PM  Could the Trade War be Bullish for Stocks? Zacks
11:40AM  AVEO Surges on Favorable Updated OS Results on RCC Drug Zacks
11:13AM  Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit Zacks
09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
Sep-10-19 01:38PM  7 Cheap Stocks to Buy in a Pricey Market Kiplinger
11:18AM  Aveo CEO says new data eases concerns about troubled kidney cancer drug American City Business Journals
05:30AM  Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients Business Wire
Sep-09-19 11:33AM  The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers Zacks
09:15AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now Zacks
07:25AM  Top Ranked Income Stocks to Buy for September 9th Zacks
Sep-08-19 09:00AM  Better Buy: Amgen vs. Celgene Motley Fool
Sep-07-19 12:30PM  Is Bristol-Myers Squibb a Buy? Motley Fool
Sep-06-19 03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
11:36AM  Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs Zacks
11:29AM  Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study Zacks
08:00AM  BMY Stock Plus Celgene Will Be A Top 5 Pharma But Should You Buy It? Investor's Business Daily
Sep-05-19 04:51PM  3 Special Situations Gurus Are Buying
10:24AM  Infinity Initiates 2 Studies for Lead Candidate IPI-549 Zacks
08:58AM  The Zacks Analyst Blog Highlights: Allegiant, Bristol-Myers, NewMarket, North American Construction and TiVo Zacks
08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
07:24AM  Bristol-Myers cancer drug Opdivo fails to meet a primary endpoint in phase 3 trial MarketWatch
07:09AM  Bristol-Myers' Opdivo fails to meet goal of brain tumor study Reuters
07:01AM  Novartis signs $840M pact with IFM Due amid fallout from AveXis deal American City Business Journals
05:10AM  Bristol-Myers Stock Slips After Brain-Cancer-Drug Disappointment
Sep-04-19 03:14PM  Here's Why Nektar Therapeutics Plummeted 38% in August Motley Fool
09:39AM  Roche Extends Offer to Acquire Spark Therapeutics Yet Again Zacks
09:22AM  5 Strong Buy Ultra-Safe Stocks for an Uncertain September Zacks
09:19AM  The Zacks Analyst Blog Highlights: TransDigm, Keysight, Bristol-Myers Squibb, NRG and Arconic Zacks
07:00AM  More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research Business Wire
Sep-03-19 05:46PM  Top-Performing Biotech ETFs YTD Zacks
09:21AM  The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie Zacks
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
07:02AM  5 Cancer-Fighting Stocks to Add to Your Portfolio Zacks
Sep-02-19 07:14AM  5 Top S&P 500 Stocks Soaring Despite Worst August Since 2015 Zacks
Aug-30-19 05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
11:33AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Alamos Gold, Americold Realty Trust, TransDigm and frontdoor Zacks
11:30AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ONEOK, Verizon Communications, Principal Financial and Omnicom Zacks
10:11AM  Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs Zacks
09:49AM  Why this biotech's new-school opioid is on hold with the FDA American City Business Journals
Aug-29-19 09:15AM  Dow Jumps 1% Despite Yield Curve Worries Zacks
08:15AM  5 Top Momentum Stocks in August Despite Market Mayhem Zacks
07:33AM  Will Treasury Yield Inversion Benefit Stocks? 5 Top Picks Zacks
Aug-28-19 06:55PM  What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals Zacks
05:19PM  6 Seth Klarman Stocks With Low Price-Earnings Ratios
01:56PM  Bristol-Myers Squibb Gains Europe's Approval for Empliciti
10:54AM  Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59B Benzinga
10:38AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health Zacks
10:15AM  Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion Zacks
10:00AM  10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond InvestorPlace
07:31AM  The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved Benzinga
06:28AM  Alexion Wins EC Nod for Soliris in Nervous System Disorder Zacks
05:56AM  Those Who Purchased Bristol-Myers Squibb (NYSE:BMY) Shares A Year Ago Have A 20% Loss To Show For It Simply Wall St.
Aug-27-19 04:16PM  European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Business Wire
11:01AM  4 Biotech Stocks to Buy That Are on the Move InvestorPlace
10:55AM  Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy? Zacks
10:05AM  Amgen to Buy Celgene's Otezla: 5 ETF Drugs Zacks
09:24AM  3 Cancer Treatment Stocks to Enrich Your Portfolio Zacks
08:58AM  Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene Zacks
08:05AM  Bristol-Myers Announces Sale of Celgene's Otezla to Amgen Zacks
08:00AM  Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO Technology PR Newswire
Aug-26-19 10:04PM  US Stock Market Overview – Stock Surge as Trump Flip Flops Lifting Dow Industrials FX Empire
05:06PM  What Happened in the Stock Market Today Motley Fool
04:34PM  Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks InvestorPlace
03:32PM  5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY InvestorPlace
01:53PM  Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen InvestorPlace
01:25PM  Hedge Funds' Most-Bought Stocks Last Quarter
01:21PM  Amgen's Proposed $13.4B Acquisition Of Celgene's Otezla: What You Need To Know Benzinga
10:57AM  Amgen Will Buy Celgene Drug in $13.4 Billion Antitrust Sale Bloomberg
09:14AM  Bristol-Meyers Deal for Celgene Moves Ahead After the Sale of Psoriasis Drug
06:46AM  Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion Reuters
06:30AM  Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion Business Wire
06:30AM  Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits PR Newswire
Aug-25-19 09:45PM  Amgen to buy Celgenes Otezla in $13.4bn deal Financial Times
05:00PM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
02:00PM  Better Buy: Biogen vs. Celgene Motley Fool
Aug-24-19 09:31AM  Why Is Bristol-Myers (BMY) Up 2.6% Since Last Earnings Report? Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; Novartis; and Presage Biosciences. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Santiago Karen MurphyControllerSep 01Option Exercise0.0064103,707Sep 04 05:17 PM
BERTOLINI ROBERT JDirectorJul 31Buy44.7211,000491,92011,397Aug 01 05:06 PM
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM